Healthcare >> Sector Roundtables >> June 1, 2009
George Huang is a biotechnology analyst at Stansberry & Associates, an
independent equity research firm. His coverage universe includes small- to mid-
cap biotechs with a strong focus in the infectious diseases, metabolic diseases,
autoimmunity, oncology and platform technologies. His research and trading
strategies are featured in two publications (The FDA Report, Phase 1 Investor).
He was the Pollard Scholar and received his PhD in Cellular and Molecular
Medicine from Johns Hopkins University and Bachelor of Science degree in Biology
from University of British Columbia. Profile
Dr. Selvaraju: There have obviously been some significant headwinds in the
industry for some time now. Primarily,
